LONDON Toumaz Technology Ltd. a developer of RF, analog and mixed signal semiconductors targeting medical electronics applications, has struck what the group terms a "strategic development and distribution alliance" with an un-named leading global medical devices business.
The new partner will put additional funds into the group for continuing product development, and has also committed to provide funding and resources to assist in gaining any necessary regulatory approvals for the technology.
Toumaz (Abingdon, England), a subsidiary of Nanoscience, says the partnership will "develop agreed solutions, incorporating Toumaz's Amx technology and its Sensium platform that will be sold into global healthcare markets with the objective of becoming global leaders in handheld and body worn wireless diagnostic and monitoring products."
Toumaz has pulled together the key core competences of ultra-low power wireless and ultra-low power signal processing first developed at Imperial College, London, and integrating these on to a system for the acquisition of data from a mobile individual.
The company recently tested its integrated Sensium platform in a device aimed at health and lifestyle monitoring. It said the chip, which taped-out on Infineon's 130-nm RF CMOS process in November 2006 less than 18 months after initial specification, has met all targeted accuracy and performance parameters in initial functional testing.
Toumaz said it would retain all the "background" intellectual property relating to its AMx platform and will be entitled to explore further revenue streams for the technology outside of the field of use being exploited jointly with its new strategic partner.
Specialist investment group Nanoscience, which acquired Toumaz two years ago in a deal that valued it at about £17.7 million, has continued funding the RF chip and system specialist's R&D and has also provided the startup with commercial and corporate expertise that has resulted in the establishment of this landmark alliance.
Professor Chris Toumazou, Chairman of Toumaz Technology Limited, commented: "The establishment of this alliance is a very positive development for Toumaz, and we now have the opportunity to provide end to end solutions in the personalized healthcare space. This has been a key strategic goal of the business that we now believe is deliverable."
Guy Spelman, Nanoscienceís CEO, added: "This is the most significant landmark in the seven year history of Toumaz as the road to commercialization is now visible."